Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer by Machackova, Eva et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Spectrum and characterisation of BRCA1 and BRCA2 deleterious 
mutations in high-risk Czech patients with breast and/or ovarian 
cancer
Eva Machackova*1, Lenka Foretova1, Mirka Lukesova1, Petra Vasickova1, 
Marie Navratilova1, Ilse Coene2, Hana Pavlu1, Veronika Kosinova1, 
Jitka Kuklova1 and Kathleen Claes2
Address: 1Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic and 2Centre for Medical 
Genetics, Ghent University Hospital, Gent, Belgium
Email: Eva Machackova* - emachack@mou.cz; Lenka Foretova - foretova@mou.cz; Mirka Lukesova - mlukesova@mou.cz; 
Petra Vasickova - vasickova@mou.cz; Marie Navratilova - mnavrati@mou.cz; Ilse Coene - Ilse.Coene@UGent.be; Hana Pavlu - pavlu@mou.cz; 
Veronika Kosinova - kosinova@mou.cz; Jitka Kuklova - jkuklova@mou.cz; Kathleen Claes - Kathleen.Claes@UGent.be
* Corresponding author    
Abstract
Background: The incidence of breast cancer has doubled over the past 20 years in the Czech
Republic. Hereditary factors may be a cause of young onset, bilateral breast or ovarian cancer, and
familial accumulation of the disease. BRCA1 and BRCA2 mutations account for an important fraction
of hereditary breast and ovarian cancer cases. One thousand and ten unrelated high-risk probands
with breast and/or ovarian cancer were analysed for the presence of a BRCA1 or BRCA2 gene
mutation at the Masaryk Memorial Cancer Institute (Czech Republic) during 1999–2006.
Methods: The complete coding sequences and splice sites of both genes were screened, and the
presence of large intragenic rearrangements in BRCA1 was verified. Putative splice-site variants
were analysed at the cDNA level for their potential to alter mRNA splicing.
Results: In 294 unrelated families (29.1% of the 1,010 probands) pathogenic mutations were
identified, with 44 different BRCA1 mutations and 41 different BRCA2 mutations being detected in
204 and 90 unrelated families, respectively. In total, three BRCA1 founder mutations (c.5266dupC;
c.3700_3704del5; p.Cys61Gly) and two BRCA2  founder mutations (c.7913_7917del5;
c.8537_8538del2) represent 52% of all detected mutations in Czech high-risk probands. Nine
putative splice-site variants were evaluated at the cDNA level. Three splice-site variants in BRCA1
(c.302-3C>G; c.4185G>A and c.4675+1G>A) and six splice-site variants in BRCA2 (c.475G>A;
c.476-2>G; c.7007G>A; c.8755-1G>A; c.9117+2T>A and c.9118-2A>G) were demonstrated to
result in aberrant transcripts and are considered as deleterious mutations.
Conclusion: This study represents an evaluation of deleterious genetic variants in the BRCA1 and
2 genes in the Czech population. The classification of several splice-site variants as true pathogenic
mutations may prove useful for genetic counselling of families with high risk of breast and ovarian
cancer.
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Background
The incidence of breast cancer has doubled over the past
20 years in the Czech Republic [1]. A family history of
breast cancer is one of the most significant risk factors for
development of the disease. Hereditary factors may cause
early onset, bilateral breast or ovarian cancer, and familial
accumulation of the disease. Approximately 5 to 10% of
all breast cancer cases, and 25 to 40% of cases diagnosed
under the age of 35 years, have hereditary origins [2].
Mutations in BRCA1  (breast cancer 1, early onset;
MIM#113705) and BRCA2 (Breast Cancer Type 2 suscep-
tibility protein; MIM#600185) account for an autosomal
dominant transmission of susceptibility to breast and
ovarian cancer. Among female BRCA1 mutation carriers,
the lifetime risk of breast cancer has been estimated at
between 65 and 85%, and the risk of ovarian cancer
between 39 and 63% [3-5]. For BRCA2 mutation carriers,
the lifetime risk for breast cancer ranges from 45 to 85%,
and between 11 and 27% for ovarian cancer [3,5]. The
large variations suggest that cancer risk associated with
BRCA mutations may be modified by other genetic factors
in addition to lifestyle and environmental conditions [6].
With the exception of alterations in the extreme carboxy-
terminal of BRCA2 (3' of the polymorphic stop codon
K3326X), all BRCA1 and BRCA2 truncation mutations are
considered to be deleterious [7,8]. Experimental data have
revealed the presence of two nuclear localisation signals
(NLS) within the final 156 amino acids of the BRCA2 pro-
tein. These data indicate that all disease-linked truncating
mutations localised upstream of the NLS are likely to be
non-functional, losing their ability to translocate to the
nucleus [9].
Aside from the many unequivocal pathogenic mutations,
several variants of unknown clinical significance have
been reported in the BRCA1 and BRCA2 genes. Messenger
ribonucleic acid (mRNA) analysis has only been per-
formed, and the pathogenic effect clearly demonstrated,
for a limited number of splice-site alterations [10,11]. In
addition, only a few missense mutations have been
accepted as deleterious disease-associated genetic altera-
tions that can be reliably used for clinical management.
When assessing the clinical significance of a detected var-
iant, several approaches of further analysis are recom-
mended to classify variants as deleterious, suspected
deleterious, of unknown (uncertain) clinical significance
or polymorphic/neutral [12].
The aim of our study was to demonstrate the pathogenity
of all suspected deleterious variants detected in the high-
risk Czech population.
Methods
Patients and criteria for testing
Patients were referred to the Masaryk Memorial Cancer
Institute (MMCI) in Brno for genetic counselling by phy-
sicians from various specialisations or were sent for test-
ing by other medical geneticists from various parts of the
Czech Republic between 1999 and 2005. All tested indi-
viduals provided a signed informed consent following
appropriate genetic counselling. Genetic testing was
offered to high-risk individuals meeting any of the follow-
ing criteria:
I. At least 3 diagnoses of breast and/or ovarian cancer in
first and/or second degree relatives, diagnosed at any age
(320 families).
II. Two affected first degree relatives (or second degree in
the case of paternal transmission) diagnosed with breast
and/or ovarian cancer, at least one of them diagnosed
before the age of 50 (252 families).
III. Any patient with a) bilateral breast, first diagnosed
before 50 (29 patients), or b) bilateral ovarian cancer,
diagnosed before 50 (7 patients), or c) both breast and
ovarian cancer, without an apparent family history of
these cancers (19 patients).
IV. Early-onset sporadic unilateral breast (121 patients) or
ovarian (19 patients) cancer cases diagnosed before the
age of 40.
V. Any male patient with breast cancer, independent of
age at diagnosis and family history (16 males who do not
fulfil criteria I or II).
VI. In several families with hereditary breast and/or ovar-
ian cancer predisposition, none of the affected relatives
was available for testing. Healthy high-risk individuals,
who had a 50% chance of being a carrier of the familial
mutation, were therefore analysed (77 families).
VII. In addition, we analysed 150 affected probands on
the borderline of our inclusion criteria (such as probands
from small families with 2 affected relatives diagnosed
between 51 to 60 years of age, or patients diagnosed
before the age of 50 with a third degree relative with
breast/ovarian cancer) referred by clinical geneticists.
Inclusion criteria I, II and VI were considered as familial
cases, whilst criteria III, IV and V were considered as severe
sporadic cases.
Mutation screening
Genomic DNA was isolated from blood samples with the
QIAamp DNA blood purification kit (Qiagen). The non-BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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radioactive protein truncation test (PTT) (Promega) was
used for analysis of exon 11 of the BRCA1 gene, and for
exons 10 and 11 of the BRCA2 gene. The remaining exons
and their splice sites were screened by Heteroduplex anal-
ysis (HA) using Mutation Detection Enhancement (MDE)
gel solution (Cambrex), essentially as described by Claes
et al. [13]. Fragments with aberrant mobility, detected on
PTT or HA gels, were sequenced on an independently
amplified polymerase chain reaction (PCR) product by
direct sequencing using the Thermo Sequenase Primer
Cycle Sequencing Kit, or the Thermo Sequenase Cy5 Dye
Terminator Cycle Sequencing Kit (Amersham Bio-
sciences), and analysed on the ALF express™ DNA
sequencer (Pharmacia). Each newly found sequence alter-
ation was confirmed by sequencing from both forward
and reverse directions. Each detected mutation was con-
firmed on an independently drawn blood sample. In the
case of a deceased patient, a germline mutation was con-
firmed on DNA isolated from non-tumour paraffin
embedded tissue.
In addition, we evaluated the frequency of large genomic
rearrangements in the BRCA1 gene with Multiplex Liga-
tion-dependent Probe Amplification, or MLPA (MRC-
Holland). More details about this study are reported else-
where [14].
cDNA analysis
All putative splice-site variants were tested by the Splice
Site Prediction Programs for their potential to alter splic-
ing [11]. Subsequently, complementary DNA (cDNA)
analysis was performed to verify the in silico results.
Total ribonucleic acid (RNA), treated with a nonsense-
mediated mRNA decay inhibitor (Puromycin), was
extracted from short-term PHA-stimulated lymphocyte
cultures [15] of the patient and from controls not carrying
the studied splice-site alteration.
The region of the BRCA1/BRCA2 cDNA encompassing the
relevant fragment was amplified by PCR. If more than two
aberrant transcripts were obtained, the PCR products
derived from cDNA templates were cloned into the vector
PCR 2.1-TOPO and transfected into Escherichia coli strain
Top10F (Invitrogen). After amplification with M13 prim-
ers, the products were resolved on agarose gels and
sequenced. The cDNA analysis approach has previously
been described in more detail by Claes et al. [11].
Nomenclature
Detected mutations and other sequence alterations are
described at the cDNA level according to the GenBank:
U14680 BRCA1 reference sequence and GenBank:
NM_000059 BRCA2 reference sequence, using the recom-
mended nomenclature system for human gene mutations
[16].
The cDNA numbering for the traditional mutation
nomenclature used in the BIC (Breast Cancer Information
Core) Database is based on reference sequences as stated
above, where the A of the ATG translation initiation
codon is at position 120 of the BRCA1 mRNA and at posi-
tion 229 of the BRCA2 mRNA, respectively. The HUGO-
approved systematic nomenclature follows the rule where
the nucleotide +1 is the A of the ATG translation initiation
codon. In the text of this article, we use the systematic
nomenclature. In the tables, both BIC and systematic
cDNA numbering are used.
Results
Deleterious BRCA mutations
In this study, we describe molecular genetic analyses of
the BRCA1 and BRCA2 genes in 1,010 unrelated high-risk
probands. Through PCR based screening methods, 188
families were identified as carrying deleterious BRCA1
mutations (34 different mutations – Table 1) and 80 fam-
ilies as harbouring deleterious BRCA2 mutations (35 dif-
ferent mutations – Table 2). Furthermore, we identified
10 different alterations in highly conserved splice sites in
15 families (Table 3), which were analysed at the mRNA
level. In 11 additional families, 6 different large intragenic
rearrangements in the BRCA1  gene were detected by
MLPA. These were further characterised and are described
in detail elsewhere [14]. Altogether, a pathogenic muta-
tion was found in 294 of 1,010 (29.1%) unrelated fami-
lies (Tables 1 to 3).
The spectrum of the BRCA1 mutations is summarised in
Tables 1 and 3. As generally reported, the majority of the
BRCA1 mutations were mutations leading to a premature
stop codon (21 different frame-shift, 9 different nonsense,
and 4 different splice-site mutations (described below).
Furthermore, we identified 4 different deleterious mis-
sense mutations localised in the 100% conserved cysteine
residues of the BRCA1 C3HC4 RING domain: p.Cys24Tyr;
p.Cys39Arg; p.Cys61Gly and p.Cys64Tyr.
All deleterious mutations identified in the BRCA2 gene
were truncating mutations (30 different frame-shift muta-
tions, 5 different nonsense mutations, and 6 different
splice-site mutations (described below)) and are summa-
rised in Tables 2 and 3.
Splice-site alterations
For all putative splice-site variants, we performed further
analyses to unequivocally determine their pathogenic
effect. We have previously reported that BRCA1
c.4185G>A and BRCA2  c.9118A-2>G lead to aberrant
transcripts [11]. In this publication, we provide results ofBMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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the effects at the cDNA level for 7 additional putative
splice-site variants that have not been described previ-
ously, i.e. two variants in the BRCA1 gene (c.302-3C>G
and c.4675+1G>A) and five in the BRCA2  gene
(c.475G>A; c.476-2>G; c.7007G>A; c.8755-1G>A and
c.9117+2T>A).
To set aside nonsense-mediated mRNA decay (NMD), an
inhibitor of the NMD pathway was used before RNA iso-
lation from lymphocyte cultures. As we had previously
found that splice-site mutations not only lead to tran-
scripts affecting the exon following or preceding the muta-
tion but may also affect other neighbouring exons, we
chose RT-PCR primers that were not in the immediately
adjacent exons.
Results of the RT-PCR experiments are shown in Figure 1.
The predicted consensus values, the experimentally deter-
mined effect on mRNA, and deduced results at the protein
level are summarised in Table 3. For 4 of the putative
splice-site mutations analysed (BRCA1  c.4675+1G>A,
BRCA2  c.476-2A>G, c.8755-1G>A and c.9117+2T>A),
aberrant splicing was anticipated as these variants affect
the highly conserved nucleotides at positions +1+2/-1-2
of the splice donor/acceptor sites.
Furthermore, we validated 3 variants outside the highly
conserved +1+2/-1–2 nucleotides. BRCA1  c.302-3C>G
activates a cryptic splice site in intron 6, leading to the
inclusion of two extra base pairs from this intron. This
results in a frame-shift and a premature termination of
translation.
The G to A transition in the last nucleotide of BRCA2 exon
5 (c.475G>A) results in a transcript lacking in frame exon
5, which was absent in control individuals. Unfortunately,
Table 1: Spectrum of frame-shift, missense and nonsense BRCA1 germline mutations detected in Czech patients.
BRCA1 exon DNA level BIC traditional nomenclature DNA level Systematic nomencl. Protein level No. of families
2 c.174C>T c.55C>T p.Gln19X 1
2 c.187_188delAG (185delAG) c.68_69del2 p.Glu23ValfsX17 7
2 c.190G>A c.71G>A p.Cys24Tyr 1
3 c.234T>C c.115T>C p.Cys39Arg 5
5 c.300T>G c.181T>G p.Cys61Gly 20
5 c.310G>A c.191G>A p.Cys64Tyr 1
11A c.962_965del4 c.843_846del4 p.Ser282TyrfsX15 1
11A c.1135dupA (1135insA) c.1016dupA p.Val340GlyfsX6 1
11A c.1159delT c.1040delT p.Leu347ArgfsX27 1
11A c.1187_1196del10 c.1068_1077del10 p.Gln356HisfsX15 1
11A c.1323delG c.1204delG p.Glu402SerfsX8 1
11A c.1522delA c.1403delA p.Lys468ArgfsX7 1
11A c.1629delC c.1510delC p.Arg504ValfsX28 1
11A c.1719C>T c.1600C>T p.Gln534X 3
11A c.1806C>T c.1687C>T p.Gln563X 6
11B c.2276dupA c.2157dupA p.Glu720ArgfsX6 2
11B c.2312_2315del4 c. 2193_2196del4 p.Glu732ArgfsX3 1
11B c.2382G>T c.2263G>T p.Glu755X 4
11B c.2530_2531delAG c.2411_2412del2 p.Gln804LeufsX5 3
11B c.2607_2616dup10 (2616_2617ins10) c.2488_2497dup10 p.Leu833X 4
11B c.2881delA c.2762delA p.Gln921ArgfsX79 2
11B c.3283delG c.3164delG p.Gly1055AlafsX4 1
11C c.3740_3745del6insAA c.3591_3626del6insAA p.Leu1209Ser25 1
11C c.3761_3762delGA c.3642_3643del2 p.Asn1215fsX3 2
11C c.3819_3823del5 c.3700_3704del5 p.Val1234GlnfsX8 29
11C c.3875_3878del4 c.3756_3759del4 p.Ser1253ArgfsX10 6
11C c.4171T>A c.4052T>A p.Leu1351X 1
12 c.4280_4281delTC c.4161_4162del2 p.Gln1388GlufsX2 1
12 c.4284_4285delAG c.4165_4166del2 p.Ser1389X 1
13 c.4458C>T c.4339C>T p.Gln1447X 1
20 c.5385dupC (5385insC; 5382insC) c.5266dupC p.Gln1756ProfsX74 75
22 c.5465G>A c.5346G>A p.Trp1782X 1
24 c.5629G>A c.5510G>A p.Trp1837X 1
24 c.5630G>A c.5511G>A p.Trp1837X 1
BRCA1 reference sequence GenBank: U14680. Mutations marked in bold had not been submitted to the BIC database from any other population 
prior to November 2007 [21].BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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no patient with both this mutation and an SNP in exons
2–10 of BRCA2 was available to allow investigation of
whether the mutant allele was still able to transcribe a full-
length product. This mutation was identified in two unre-
lated families that were too small to evaluate segregation.
RT-PCR with a forward primer located in exon 11 and a
reverse primer in exon 15 revealed that the BRCA2
c.7007G>A mutation, in the last nucleotide of exon 13, is
not a missense mutation (p.Arg2336His). We found a
transcript lacking exon 13, a transcript lacking exons 12
and 13, and a transcript lacking exon 12. The transcript
lacking exon 12 is present at about the same level in blood
lymphocytes of both the patient with the mutation and a
control person (data of the cloning experiments not
shown). The BRCA2 c.7007G>A mutation was found in 2
unrelated families: in an affected female with a severe
family history of breast cancer, fulfilling criterion I, and in
an affected male with a maternal aunt and cousin diag-
nosed with breast cancer.
Mutation detection rates
BRCA1 mutations were found to be about 2 times more
frequent than BRCA2 mutations in our study population.
Mutation detection frequencies (deleterious and splice-
site mutations and large intragenic rearrangements) in
relation to the inclusion criteria are summarised in Table
4. Surprisingly, the highest mutation frequency (14 out of
19 cases, or 73.7%) was obtained in apparently sporadic
patients diagnosed with both breast and ovarian cancers.
By re-evaluation of the pedigrees, we found that the
apparent lack of a family history might have been due to
a small number of relatives and/or paternal transmission
in these families. As expected, a higher mutation detection
Table 2: Spectrum of frame-shift and nonsense BRCA2 germline mutations detected in Czech patients.
BRCA2 exon DNA level BIC traditional nomenclature DNA level Systematic nomencl. Protein level No. of families
3 c.534dupA c.306dupA p.Leu103IlefsX10 1
5 c.690_691delAA c.462_463del2 p.Asp156X 1
9 c.983_986del4 c.755_758del4 p.Asp252ValfsX24 1
10 c.1617_1618delAG c.1389_1390del2 p.Val464GlyfsX3 2
10 c.2024_2028del5 c.1796_1800del5 p.Phe559X 1
10 c.2041dupA (2041–2042insA) c.1813dupA p.Ile605AsnfsX11 2
11A c.3036_3039del4 c.2808_2811del4 p.Ala938ProfsX21 5
11A c.3304A>T c.3076A>T p.Lys1026X 1
11A c.3337C>T c.3109C>T p.Gln1037X 1
11B c.3972_3975del4 c.3744_3747del4 p.Ser1248ArgfsX10 1
11B c.4075_4076delGT c.3847_3848del2 p.Val1283LysfsX2 2
11C c.5073_5074delCT c.4845_4846del2 p.Leu1616LysfsX2 1
11C c.5270_5271delGT c.5042_c.5043del2 p.Val1681GlufsX7 1
11D c.5441_5444del4 c.5213_5216del4 p.Thr1738IlefsX2 1
11D c.5869_5872del4 c.5641_5644del4 p.Lys1881GlnfsX27 1
11D c.5873C>A c.5645C>A p.Ser1882X 4
11D c.5950_5951delCT c.5722_5723del2 p.Leu1908ArgfsX2 1
11D c.5991dupT c.5763dupT p.Ala1922CysfsX2 1
11D c.6017delT c.5789delT p.Leu1930TyrfsX33 1
11E c.6633_6637del5 c.6405_6409del5 p.Asn2135LysfsX3 1
11E c.6677_6678delAA c.6449_6450del2 p.Lys2150SerfsX25 3
11E c.6696_6697delTC c.6468_6469del2 p.Gln2157IlefsX18 1
11E c.6866delC c.6638delC p.Ser2213X 2
11E c.6982dupT (6982–6983insT) c.6754dupT p.Ser2252PhefsX9 1
14 c.7379_7380delAA c.7151_7152del2 p.Gln2384ArgfsX7 1
15 c.7699C>T c.7471C>T p.Gln2491X 1
17 c.8141_8145del5 (8138_8142del5) c.7913_7917del5 p.Phe2638fsX 15
18 c.8270_8271delCA c.8042_8043del2 p.Thr2681CysfsX11 3
18 c.8397_8400dup4 (8400_8401ins4) c.8169_8172dup4 p.Trp2725MetfsX3 1
19 c.8591G>A c.8363G>A p.Trp2788X 1
20 c.8765_8766delAG c.8537_8538del2 p.Glu2846GlyfsX22 14
23 c.9325dupA c.9097dupA p.Thr3033AsnfsX11 1
25 c.9631delC c.9403delC p.Leu3135PhefsX28 4
25 c.9663_9664delGT c.9435_9436del2 p.Ser3147CysfsX2 1
25 c.9691_9695del5ins8 c.9463_9467del5ins8 p.Phe3155GlufsX9 1
BRCA2 reference sequence GenBank: U43746. Mutations marked in bold had not been submitted to the BIC database from any other population 
prior to November 2007 [21].BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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rate was obtained in breast and ovarian (HBOC) cancer
families fulfilling criteria I and II (96/160, or 60%) as
compared to breast cancer only (HBC) families fulfilling
the same criteria (114/412, or 27.7%).
Six out of 16 male breast cancer patients (37.5%) carried
a deleterious mutation. Unexpectedly, the same number
of mutations was identified in the BRCA2  gene
(c.7913_7917del5; c.9403delC, and the splice-site muta-
tion c.7007G>A) as in the BRCA1 gene (2 males carrying
c.5266dupC and one patient with c.3700_3704del5). The
average age of male breast cancer diagnosis in mutation
carriers was 72.5 years (ranging from 58 to 80 years). Four
of the mutation carriers reported a family history of breast
or prostate cancer but did not meet inclusion criteria II.
The average age at diagnosis of breast cancer of the 10
males without a BRCA mutation was 57.2 years, ranging
from 37 to 80 years. In addition, we identified rare vari-
ants of unknown significance in four male patients: 2 in
BRCA1  (c.5277+48_5277+59dup12; c. 5277+78G>A)
and 2 in the BRCA2  gene (p.Ala75Pro;
c.10095delCins11).
Table 3: Splice-site alterations detected in Czech high-risk breast/ovarian cancer patients.
DNA level Gene/splice 
site BIC/systematic 
nomenclature
Predicted consensus values* RNA level (systematic 
nomencl.) experimentally 
determined
Protein level deduced Criteria of 
affected probands
Comment
acceptor donor
BRCA1/IVS6, wild type 0,99 r.302-2_302-1ins p.Tyr101X III (bi-brca 35,55)
c. 421-3C>G/c.302-
3C>G
new 0,9 at position -2
BRCA1/exon 12, wild 
type
0,95 r.4097_4185del p.Gly1366AlafsX8 I (HBC) Cfr. Ref. [11]
c.4304G>A/c.4185G>A 0,36
BRCA1/IVS15, wild type 0,44 r. [=, 4358_4675del, 
4485_4675del, 4665_4675del, 
4358_4484del+4665_4675del]
p. [=, Ala1453_Leu1558del, 
Ser1496GlyfsX14, 
Gln1556GlyfsX14, 
Ala1453GlyfsX10]
VII (brca 42)
c.4794+1G>A/
c.4675+1G>A
not predicted
BRCA1/IVS18, wild type 0,95 Not analysed; all known 
mutation carriers were deceased
p.? II (HBC) Highly suspected 
to be deleterious.
c.5271+2dupT/
c.5152+2dupT
not predicted
BRCA2/exon 5, wild 
type
0,95 r.326_475del p.Phe143GlyfsX26 I (HBC)
c.703G>A/c.475G>A 0,46 VI (HBC-FA-I)
BRCA2/IVS5, wild type 0,91 r. [326_516del, 476_516del] p. [Phe143ValfsX12, 
Val159GlyfsX10]
I (HOC); II (HBC)
c.704-2A>G/c.476-
2A>G
not predicted IV (brca 27)
IV(brca 34)
BRCA2/exon13, wild 
type
0,99 r. [6842_6937del, 
6842_7007del, 6938_7007del]
p. [Glu2281_Gly2313del, 
Gly2280AlafsX31, 
Gly2313Ala fsX31]
I (HBC) Cfr. Ref. [25]
c.7235G>A/c.7007G>A not predicted V(male brca)
BRCA2/IVS21, wild type not predicted r.8755_8953del p.Gly2919fsX3 II (HBC)
c.8983-1G>A/c.8755-
1G>A
not predicted
BRCA2/IVS23, wild type 0,57 r.8954_9117del p.Val2985GlyfsX4 I (HBOC)
c.9345+2T>A/
c.9117+2T>A
not predicted
BRCA2/IVS23, wild type 1,00 r.9118_9124del p.Val3040MetfsX20 I (HBC) Cfr. Ref. [11]
c.9346-2A>G/c.9118-
2A>G
cryptic 0,7
* Predicted consensus values by the Splice Site Prediction Program: Neural Networks [23].BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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A deleterious mutation was detected in 20 out of 77
healthy, unaffected probands (26%; 15 in BRCA1 and 5 in
the BRCA2 gene) with a severe family history of breast
and/or ovarian cancer but no living affected relative. Fur-
thermore, we identified a deleterious mutation in 20 out
of 150 affected probands (13.3%; 12 in BRCA1 and 8 in
the BRCA2 gene) who did not fully meet our inclusion cri-
teria for testing but who were referred by genetic counsel-
lors.
Discussion
Molecular genetic analysis for the BRCA1  and  BRCA2
genes has been available at the MMCI since 1999. By the
end of 2006, an unequivocal deleterious mutation had
been identified in 294 high-risk Czech probands out of
1,010 probands selected for genetic testing (29.1%). Sim-
ilar inclusion criteria are used in other centres [17].
In familial cases, we obtained a mutation detection rate of
36.7% (210/572) in sporadic bilateral breast, bilateral
ovarian or breast, and ovarian cancer patients 43.6% (24/
55) but only 10.7% (13/121) in early onset unilateral
breast cancer patients. However, the latter is slightly
higher than generally reported in Europe (< 5–9%) in
early onset sporadic cases [18,17]. BRCA1 mutations were
twice as frequent as BRCA2 mutations in our study popu-
lation. The presence of an ovarian cancer case turned out
to be a good indicator for the presence of a causative
BRCA mutation: the highest mutation detection rates were
obtained in apparently sporadic patients diagnosed with
both breast and ovarian cancer (73,7%) and in breast-
ovarian cancer families (about 60%). This detection rate
seems to be rather high when compared with ones
reported for example in Germany (43%) or Belgium using
similar inclusion criteria [18,17]. Detection rate highly
depends on severity of family history and this might be
RT-PCR results for the splice-site mutations identified in our patient population Figure 1
RT-PCR results for the splice-site mutations identified in our patient population. Below the picture we indicate the 
position of the RT primers used. C = control. A detailed description of the relevant fragments obtained can be found in Table 
3. However, we omitted in this Table details about several novel alternative transcripts containing intronic sequences with high 
acceptor/donor scores at the 5'/3' ends, complicating the interpretation of the results and of which the clinical relevance is cur-
rently unknown. For instance, cloning RT-PCR products spanning exons 21 to 26 revealed several novel alternative transcripts 
containing insertions from sequences of introns 24 and 25 (cfr. extra bands above the full length fragment in control persons 
and bands around 920–930 bp in the patient with BRCA2 c.9117+2T>A, representing transcripts lacking exon 23 but containing 
these intronic sequences. Similar observations were obtained for the RT-PCR analyses for BRCA2 c.8755-1G>A.BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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result of accumulating of very severe affected families
seeking genetic advice in our population.
The majority of the BRCA1 and 2 deleterious mutations
lead to a premature termination of translation. As the pro-
tein truncation test was used for screening BRCA1 exon 11
and BRCA2 exons 10 and 11, missense mutations were
not detectable in these exons. To date, however, no
undoubtedly deleterious missense mutations have been
reported for these exons. Truncating mutations may be
assumed to cause disease, but the pathogenic effect of mis-
sense and intronic variants is more equivocal. Only the
p.Cys24Tyr; p.Cys39Arg; p.Cys61Gly and p.Cys64Tyr mis-
sense mutations in the BRCA1 gene are classified as dele-
terious mutations. These substitutions take place in the
100% conserved cysteine residues of the BRCA1 C3HC4
RING domain. All these missense mutations in the Zn2+-
binding residues of the C3HC4 RING domain have previ-
ously been experimentally shown to abolish dimerization
of BRCA1 with the BARD1 protein, resulting in loss of
ubiquitin protein ligase activity and causing γ-radiation
hypersensitivity [19,20]. The p.Cys61Gly is one of the
most frequent founder BRCA1 mutations found in the
Czech Republic, as well as in many other European coun-
tries [21].
Five mutations (BRCA1:  p.Cys61Gly, c.5266dupC,
c.3700_3704del5, and BRCA2:  c.7913_7917del5 and
c.8537_8538delAG) represent 52% of all mutations
detected in our study population. Although there was a
diversity of mutations in both genes, there are strong
Slavic founder effects, particularly for two BRCA1 muta-
tions (p.Cys61Gly, and c.5266dupC) found as founder
mutations in Poland [21,22]. The BRCA1
c.3700_3704del5 mutation is a frequent mutation in Ger-
many [17,21]. Three BRCA1  Czech founder mutations
Table 4: Summary of deleterious mutations in BRCA genes identified in relation to inclusion criteria and phenotype.
Inclusion criteria and 
phenotype
Number of families/
patients
BRCA1 mutation N (%; 95% 
CI)
BRCA2 mutation N (%; 95% 
CI)
Overall mutation N (%; 
95% CI)
I. HOC + HBOC 120 61 (50.8%; 41.6%–60.1%) 12 (10.0%; 5.3%–16.8%) 73 (60.8%; 51.5%–69.6%)
I. HBC 200 41 (20.5%; 15.1%–26.8%) 24 (12.0%; 7.8%–17.3%) 65 (32.5%; 26.1%–39.5%)
I. Overall 320 102 (31.9%; 26.8%–37.3%) 36 (11.3%; 8.0%–15.2%) 138 (43.1%; 37.6%–48.8%)
II. HOC + HBOC 40 22 (55.0%; 38.5%–70.7%) 1 (2.6%; 0.1%–13.2%) 23 (57.5%; 40.9%–73.0%)
II. HBC 212 25 (11.8%; 7.8%–16.9%) 24 (11.3%; 7.4%–16.4%) 49 (23.1%; 17.6%–29.4%)
II. Overall 252 47 (18.7%; 14.0%–24.0%) 25 (10.0%; 6.5%–14.3%) 72 (28.6%; 23.1%–34.6%)
I.+II. Familial cases HOC + 
HBOC
160 83 (51.9%; 43.8%–59.8%) 13 (8.2%; 4.4%–13.5%) 96 (60.0%; 52.0%–67.7%)
I.+II. Familial cases HBC 412 66 (16.0%; 12.6%–19.9%) 48 (11.7%; 8.7%–15.1%) 114 (27.7%; 23.4%–32.3%)
I.+II. Familial cases – 
overall
572 149 (26.0%; 22.5%–29.9%) 61 (10.7%; 8.3%–13.5%) 210 (36.7%; 32.8%–40.8%)
III.A Bilateral breast cancer 
patient
29 5 (17.2%; 5.8%–35.8%) 4 (13.8%; 3.9%–31.7%) 9 (31.0%; 15.3%–50.8%)
III.B Bilateral ovarian 
cancer patient
7 1 (14.3%; 0.4%–57.9%) 0 (0.0%; 0.0%–0.0%) 1 (14.3%; 0.4%–57.9%)
III.C Patient with breast 
and ovarian cancer
19 11 (57.9%; 33.5%–79.7%) 3 (15.8%; 3.4%–39.6%) 14 (73.7%; 48.8%–90.9%)
III. Duplex cancer 
patients -overall
55 17 (30.9%; 19.1%–44.8%) 7 (12.7%; 5.3%–24.5%) 24 (43.6%; 30.3%–57.7%)
IV. Early onset ovarian 
cancer patient
19 1 (5.3%; 0.1%–26.0%) 0 (0.0%; 0.0%–0.0%) 1 (5.3%; 0.1%–26.0%)
IV. Early onset breast 
cancer patient
121 7 (5.8%; 2.4%–11.6%) 6 (5.0%; 1.8%–10.5%) 13 (10.7%; 5.8%–17.7%)
IV. Overall 140 8 (5.7%; 2.5%–10.9%) 6 (4.3%; 1.6%–9.1%) 14 (10.0%; 5.6%–16.2%)
V. Male breast cancer 16 3 (18.8%; 4.0%–45.6%) 3 (18.8%; 4.0%–45.6%) 6 (37.5%; 15.2%–64.6%)
VI. Healthy person in high-
risk (I.) family
77 15 (19.5%; 11.3%–30.1%) 5 (6.5%; 2.1%–14.5%) 20 (26.0%; 16.6%–37.2%)
VII. Out of criteria families 150 12 (8.0%; 4.2%–13.6%) 8 (5.3%; 2.3%–10.2%) 20 (13.3%; 8.3%–19.8%)
Abbreviations: inclusion criteria – see Methods section; mutation – only deleterious mutations summarised in Table 1 and Table 2 are considered; CI 
– Confidence Interval; HOC – hereditary ovarian cancer syndrome; HBOC – hereditary breast and ovarian cancer syndrome; HBC – hereditary 
breast cancer only syndrome.BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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(p.Cys61Gly, c.3700_3704del5, and c.5266dupC)
accounted for 9.8%, 14.2% and 36.8% of the BRCA1
mutations identified, respectively. A Czech founder effect
is evident for two BRCA2 mutations (c.7913_7917del5
and c.8537_8538del2) that are reported elsewhere only
from Canada and the USA [21]. These BRCA2 mutations
accounted for 15.6% and 16.7% of the BRCA2 mutations
identified, respectively.
A broad spectrum of other mutations demonstrates the
genetic diversity of the Czech population and reflects the
spectrum of mutations found in other European countries
[21]. The Czech population is mainly of Slavic origin. Due
to its location in Central Europe, however, and historical
influences during past centuries, when the Czech region
was a part of the Austro-Hungarian Empire, an influx of
other nations is evident.
All putative splice-site mutations were tested computa-
tionally for their ability to change the donor/acceptor
score in silico, as well as to elucidate the creation or activa-
tion of cryptic splice sites. For all except one (BRCA1
c.4675+1G>A), the novel splice sites were correctly iden-
tified by the Neural Networks prediction program,
thereby demonstrating its usefulness [23].
For several variants (BRCA1: c.302-3C>G; c.4675+1G>A
and  BRCA2  c.475G>A, c.476-2>G; c.7007G>A; c.8755-
1G>A; c.9117+2T>A), reliable RT-PCR data were not
available from the literature or the BIC database. For
genetic counselling purposes, it is extremely important to
differentiate between deleterious and polymorphic splice-
site alterations. Analysis at the mRNA level allowed us to
identify alterations leading to aberrant splicing. Especially
for genetic alterations outside the almost 100% conserved
+1/+2 and -1/-2 nucleotides, RT-PCR analyses can con-
tribute to a correct and definitive clinical interpretation.
We clearly demonstrate here that BRCA1 c.302-3C>G and
BRCA2 c.475G>A, c.7007G>A lead to aberrant splicing.
In general, splice-site alterations lead to skipping of the
complete exon following the acceptor or preceding the
donor site in which the mutation is located. This was
indeed what we found for BRCA1 c.4185G>A and BRCA2
c.475G>A; c.9117+2T>A and c.8755-1G>A. Other muta-
tions result in the creation of a novel splice site or activa-
tion of a cryptic splice site, such as was found for BRCA1
c.302-3C>G and BRCA2 c.9118-2A>G.
Mutations in splice sites of some exons lead to multiple
exon skipping. For example, mutations in the splice sites
of BRCA2 exon 6 seem to also affect exon 5, as observed
from RT-PCR analyses for c.476-2A>G and the previously
reported c.516+1G>A mutation [[11], Figure 1]. A further
example is the BRCA1 c.4675+1G>A mutation in intron
15. mRNA analysis revealed several different transcripts,
including some with a skip of exon 14. Multiple exon
skipping has previously been shown to be associated with
mutations in 5' as well as 3' splice sites in several genes
[24]. By the identification and further functional analyses
of such splice mutations, new regulatory elements and
mechanisms involved in splicing may be revealed.
The BRCA2 c.7007G>A mutation, in the last nucleotide of
exon 13, was previously studied by RT-PCR with primers
located in exons 12 and 14, revealing only a transcript
lacking exon 13 [25]. As we chose RT-PCR primers that
were not in the immediately adjacent exons, we discov-
ered a more complex splicing pattern, i.e. a transcript lack-
ing exon 13, a transcript lacking exons 12 and 13, and a
transcript lacking exon 12. The latter transcript was
present at the same level in control persons. An exon 12
alternatively spliced BRCA2 transcript has previously been
described as a major alternative BRCA2 transcript with an
expression level of about 10% in normal breast tissue rel-
ative to the wild type BRCA2 transcript. The expression
level of the delta12-BRCA2 transcript has been shown to
be higher in some tumour tissues compared with their
normal breast tissues [26].
In addition, our cDNA analyses revealed several novel
alternative transcripts containing intronic sequences with
high acceptor/donor scores at the 5'/3' ends. Further
investigations are required to determine the prevalence of
these transcripts in different tissues and to define their
possible role. A limitation of our studies is that they were
performed on transcriptional products of peripheral lym-
phocytes, rather than on the breast or ovarian tissues that
are considered to be the sites of initial abnormalities in
BRCA1/2-related tumors. Further studies are needed to
assess whether different quantitative and/or qualitative
effects of the alterations investigated are observed in these
tissues.
Numerous BRCA1 and BRCA2 sequence alterations iden-
tified during screening are kept in the laboratory database.
Nonsynonymous single nucleotide polymorphisms still
may have the potential to represent modifiers of inherited
susceptibility. As deleterious germline mutations in
BRCA1 and BRCA2 confer a greatly increased risk of breast
cancer, some sequence variants may be only moderate or
low penetrant alleles.
Conclusion
We detected 204 families harbouring deleterious BRCA1
mutations (44 different), and 90 families harbouring
BRCA2 mutations (41 different). BRCA1 mutations were
found to be about 2 times more frequent than BRCA2
mutations in high-risk members of the Czech population,
based on our study population. Mutation detection fre-BMC Cancer 2008, 8:140 http://www.biomedcentral.com/1471-2407/8/140
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quencies (deleterious and splice-site mutations and large
intragenic rearrangements) in relation to the inclusion cri-
teria were highest in the group of patients diagnosed with
both breast and ovarian cancers (73.7%) and in familial
cases with clustering of breast and ovarian cancers in first
and second degree relatives (60%).
Five founder mutations, three BRCA1  (c.5266dupC;
c.3700_3704del5; p.Cys61Gly) and two BRCA2  muta-
tions (c.7913_7917del5; c.8537_8538del2), account for
52% of all detected mutations. These mutations could be
used as a first-step screen. However, the screening of the
whole region of both genes is highly indicated for high-
risk Czech breast/ovarian cancer patients.
We evaluated 9 putative splice-site variants at the cDNA
level. Three splice-site variants in the BRCA1 gene (c.302-
3C>G; 4185G>A and c.4675+1G>A) and six splice-site
variants in the BRCA2  gene (c.475G>A; c.476-2>G;
c.7007G>A; c.8755-1G>A; c.9117+2T>A and c.9118-
2A>G) were demonstrated to result in aberrant transcripts
and are considered as deleterious mutations. As deleteri-
ous germline mutations in BRCA1 and BRCA2 confer a
greatly increased risk of breast cancer, some sequence var-
iants in both genes might be candidates for moderate or
low penetrance alleles. Each sequence variant detected in
high-risk probands, therefore, has to be evaluated through
a complex approach to establish the clinical consequence.
A result obtained through genetic testing for hereditary
breast and ovarian cancer has great impact on the medical
management of a patient and accurate interpretation is,
therefore, imperative.
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